Intriguingly, a phase II study has verified that regorafenib is also active in the context of second-line treatment in patients with imatinib-resistant GIST, and that secondary mutation types in KIT can be a predictor for the efficacy of regorafenib [53]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.